(MZX) Masterflex SE - Ratings and Ratios

Masterflex SE, a Germany-based industrial group established in 1987, specializes in high-performance hoses, connecting systems, and precision-engineered components for diverse industrial applications. The company operates through multiple brands, each catering to specific sectors: Masterflex for medical technology, life sciences, renewable energy, aviation, automotive, and e-mobility; Matzen & Timm for aerospace, special vehicle construction, and mechanical engineering; Novoplast Schlauchtechnik for extruded tubes and profiles; Fleima-Plastic for injection-molded parts and modules in medical technology, cosmetics, and food technology; and Masterduct for HVAC systems. Its product portfolio includes spiral, clip, film, monolayer, multilayer, co-extruded, and micro-extruded hoses, as well as connectors, clamps, manifolds, and specialized membranes. The company is headquartered in Gelsenkirchen, Germany, and serves clients across Europe and internationally.

From a technical perspective, Masterflex SE (XETRA:MZX) is currently trading at 10.10 EUR, slightly above its 20-day moving average of 10.08 but marginally below its 50-day moving average of 9.84. The stock is trading near its 200-day moving average of 9.87, indicating a neutral long-term trend. The Average True Range (ATR) of 0.20 reflects low volatility. On the fundamental side, the company has a market capitalization of 85.60M EUR, with a price-to-earnings (P/E) ratio of 10.00 and a price-to-book (P/B) ratio of 1.35, indicating moderate valuation. The return on equity (RoE) stands at 13.80%, signaling efficient profitability. The price-to-sales (P/S) ratio of 0.85 suggests the stock may be undervalued relative to its revenue generation.

3-Month Forecast (Technical and Fundamental Outlook): Based on the current technical setup, MZX is expected to consolidate near its 50-day moving average of 9.84, with potential resistance at the 10.20 level. The low ATR of 0.20 suggests limited price movement in the near term. Fundamentally, the companys focus on high-margin industrial and medical applications, coupled with its diversified brand portfolio, positions it for stable growth. However, the lack of a forward P/E figure and the current valuation multiples suggest a cautious outlook. The stock is likely to trade in a narrow range between 9.60 and 10.40 over the next three months, with breakout potential dependent on macroeconomic conditions and sector-specific developments.